NCT07175233尚未招募2 期
A Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 184
- 试验地点
- 2
- 主要终点
- Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 16 (W16).
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult patients (18-75 years) with moderate to severe AD suitable for systemic therapy.
Approximately 184 subjects with moderate to severe AD are planned to be randomized in a 1: 1: 1: 1 ratio to SIM0278 low dose, SIM0278 medium dose, SIM0278 high dose, or placebo. Subjects were stratified at randomization by baseline disease severity (moderate [IGA = 3] VS severe [IGA = 4]).
The study consisted of 4 phases: screening, double-blind induction, open-label maintenance, and safety follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Atopic dermatitis was diagnosed at screening (according to the American Academy of Dermatology consensus criteria for atopic dermatitis, 2014);
- •Use of a stable dose of emollients at least twice daily at sites of AD involvement starting at least 7 days prior to baseline;Alternatively, if the subject is using a prescribed emollients or moisturizers containing ceramide, urea, filaggrin degradation products, or hyaluronic acid prior to the Screening Visit, they may continue in the study but require a stable dose at least twice daily at the AD affected site starting at least 7 days prior to baseline;
- •Female and male subjects are willing to use protocol-required contraception from the Screening Visit until at least 90 days after the last dose and do not plan to become pregnant or donate sperm/eggs during this period.
排除标准
- •The subject was in an acute exacerbation of AD at baseline (e.g., the subject had a tendency to rapidly develop erythroderma or erythroderma in a short period of time, whichever was judged by the investigator);
- •Previous drug therapy with IL-2 or IL-2 analogues (including clinical studies);
- •Use of other immunomodulatory biologics within 3 months prior to baseline or within 5 drug half-lives, whichever is longer, including, but not limited to, anti-IL-23 (e.g., guselkumab), anti-IL-12/23 (e.g., ustekinumab), anti-IL-17 (e.g., secukinumab), or anti-IgE (e.g., omalizumab);
- •Use of cell depleting agents (e.g. rituximab) within 6 months prior to baseline;
- •Use of topical drugs for the treatment of AD or that may affect the assessment of the condition of AD within 2 weeks prior to baseline, including but not limited to TCS, TCI, phosphodiesterase-4 (PDE-4) inhibitors, Janus kinase (JAK) inhibitors, aromatic hydrocarbon receptor agonists, or Chinese herbal or herbal treatments, etc.;
- •≥ 2 bleaching baths per week within 2 weeks prior to baseline;
- •Systemic treatment (except glucocorticoid inhalers and nasal sprays) with glucocorticoids or other immunosuppressive/immunomodulatory drugs (e.g., cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, or oral JAK inhibitors) within 8 weeks prior to baseline;
- •Use of systemic Chinese herbal medicine within 4 weeks prior to baseline ;
- •Phototherapy (narrow-band ultraviolet B (NBUVB), ultraviolet B (UVB), ultraviolet A (UVA), psoralen + ultraviolet A (PUVA)) tanning beds or any other phototherapy within 4 weeks prior to baseline;
- •Use of any investigational drug/therapy within 3 months or 5 drug half-lives (whichever is longer) prior to baseline;
研究组 & 干预措施
cohort 1- Low dose group
Experimental
干预措施: SIM0278 injection (Drug)
cohort 2-Medium dose group
Experimental
干预措施: SIM0278 injection (Drug)
cohort 3-High dose group
Experimental
干预措施: SIM0278 injection (Drug)
cohort 4- placebo group
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 16 (W16).
时间窗: At Week 16 (W16)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityObesityNCT06862908Innovent Biologics (Suzhou) Co. Ltd.141
已完成
3 期
Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19Mild to Moderate COVID-19NCT05620160Guangdong Raynovent Biotech Co., Ltd1,359
进行中（未招募）
3 期
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)Pulmonary Emphysema in Alpha-1 PI DeficiencyNCT01983241Grifols Therapeutics LLC345
招募中
2 期
The Study of CM326 in Moderate-to-severe Atopic DermatitisModerate-to-severe Atopic DermatitisNCT05671432Keymed Biosciences Co.Ltd240
招募中
2 期
The Study of GR1802 in Patients With Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis with Nasal PolypsNCT05873803Genrix (Shanghai) Biopharmaceutical Co., Ltd.70